Vivesto (VIVE) Q4 2024 earnings summary

Executive summary

• Achieved key milestones in development programs, including regulatory progress for Paccal Vet and a strategic options agreement for Apealea in China, Hong Kong, Macao, and Taiwan.

• Continued cost reduction and operational streamlining, resulting in improved financial results year-over-year.

• Strengthened Cantrixil program with new preclinical results and patent application for hematological cancer.

• Final report from Docetaxel micellar phase Ib study confirmed good tolerability and clinical activity; further development requires external partnership.

Financial highlights

• Q4 2024 net sales were SEK 0 thousand (0); full-year net sales also SEK 0 thousand (0).

• Q4 operating loss improved to SEK -10,955 thousand (vs. -64,895); full-year operating loss SEK -41,962 thousand (vs. -132,171).

• Q4 net loss after tax SEK -10,711 thousand (vs. -64,360); full-year net loss SEK -39,754 thousand (vs. -128,740).

• Cash and short-term investments at year-end SEK 32,287 thousand (77,042).

• Equity at year-end SEK 158,328 thousand (197,799); equity ratio 92% (90%).

Outlook and guidance

• Interim results from Paccal Vet pilot study in dogs expected in H1 2025; potential for registration study to follow.

• Preparations for Pre-IND meeting for Apealea in China ongoing; key regulatory updates anticipated in 2025.

• Additional Cantrixil preclinical and clinical study results expected in H1 2025.

• Financial runway expected to last through 2025, with main owner providing a SEK 10 million credit facility in Q1 2025.